Send to

Choose Destination
See comment in PubMed Commons below
Int J Tuberc Lung Dis. 2006 Jan;10(1):19-23.

Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review.

Author information

  • 1Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah-Tiqva 49100, Israel.



The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis resistant to at least isoniazid (INH) and rifampicin, is a threat to global TB control.


To appraise evidence of the effectiveness of treatment of latent TB infection (LTBI) in people at risk for developing active MDR-TB.


Systematic review of comparative studies of people treated and not treated for LTBI following exposure to MDR-TB.


PubMed, EMBASE, LILACS and the Cochrane Library (December 2004).


Two observational studies met inclusion criteria. A prospective cohort study found individualised tailored treatment to be effective for preventing active TB in children (OR = 0.20, 95%CI 0.04-0.94), while a retrospective cohort study found INH not to be effective (OR = 0.46, 95%CI 0.07-2.32).


Evidence of the effects of treatment of LTBI in people exposed to MDR-TB is extremely limited in both quantity and quality. The increasing global spread of MDR-TB and the difficulties in treating it emphasise the need for effective preventive measures. Ideally, this issue should be addressed in a randomised controlled trial. Until such a trial is conducted, routine clinical data collected as part of existing TB control programmes could be useful and can be generated relatively easily.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ingenta plc
    Loading ...
    Support Center